Resistant Hypertension in Chronic Kidney Disease

316

Table 19.2

Clinical studies on interventional treatments of resistant hypertension in chronic kidney disease patients

Hering et al.

Ott et al.

Kiuchi et al.

Wallbach et al.

Patients (

n)

15

27

30

23

Age (years)

61 ± 9

63 ± 9

55 ± 10

61 ± 10

Number of antihypertensive drugs

5.6 ± 1.3

6.2 ± 1.1

4.6 ± 1.3

6.6 ± 1.6

Method of intervention

RDN

RDN

RDN

B AT

Baseline

6 months after intervention

Baseline

12 months after intervention

Baseline

24 months after intervention

Baseline

6 months after intervention

Office SBP (mmHg)

174 ± 22

142***

156 ± 12

136 ± 19***

185 ± 18

131 ± 15***

161 ± 32

144 ± 32**

Office DBP (mmHg)

91 ± 16

76***

82 ± 13

74 ± 14**

107 ± 13

87 ± 9***

87 ± 15

77 ± 17**

eGFR (ml/min)

31 ± 9

29 ± 7

48 ± 12

49 ± 15

62 ± 23

88 ± 40***

54 ± 28

60 ± 26*

UACR(mg/g creatinine)

592 ± 955

355 ± 276

• 
  

99

11***

48

45*

Proteinuria(mg/g creatinine)

• 
  


• 
  


• 
  

284

136*

SBP

systolic blood pressure,

DBP

diastolic blood pressure,

eGFR

estimated glomerular filtration rate,

RDN

renal denervation,

BAT

baroreflex activation ther

• 
  

apy,

UACR

urinary albumin-to-creatinine ratio; *p<0.05; **p<0.01; ***p<0.001

M. Adamczak et al.